A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
A phase 1/2 trial of Raludotatug deruxtecan, Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) is a phase 1/2 interventional study registered as NCT06843447 by Merck Sharp & Dohme LLC, with 605 participants planned, started 2025-04-15 and due to reach its primary completion in 2029-03-27. Interventions recorded: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or
Shares Gemcitabine, Bevacizumab, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin.
- TrialA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Shares Gemcitabine, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.
- TrialCATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Paclitaxel / nab-paclitaxel, Merck & Co. (MSD), Carboplatin, Pembrolizumab.